Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Study of Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Patients With Metastatic Breast Cancer

NCT02824575 is registered in ClinicalTrials.gov with Montefiore Medical Center as lead sponsor.

NCT NCT02824575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02824575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Study of Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Patients With Metastatic Breast Cancer
Lead sponsor
Montefiore Medical Center
Phase
Phase 1
Overall status
Terminated
Start date
July 31, 2016
Completion date
December 27, 2021
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast adenocarcinoma, breast cancer, human epidermal growth factor 2 negative carcinoma of breast, recurrent breast carcinoma, stage iv breast cancer